Wedbush Comments on Biogen's FY2025 Earnings (NASDAQ:BIIB)

Key Points

• Wedbush analysts have reduced Biogen's FY2025 earnings per share estimate from $15.96 to $15.66, while maintaining a "Neutral" rating and a target price of $135.00.
• Biogen's stock currently has a consensus rating of "Hold" among analysts, with 11 rating it as a Buy and a consensus price target of $180.69.
• In recent trading, Biogen shares opened at $143.66, with a year low of $110.04 and a high of $192.16, reflecting volatility in the stock's performance.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of Biogen in a research report issued on Tuesday, October 14th. Wedbush analyst L. Chico now forecasts that the biotechnology company will earn $15.66 per share for the year, down from their prior estimate of $15.96. Wedbush currently has a "Neutral" rating and a $135.00 target price on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q1 2026 earnings at $4.02 EPS, Q2 2026 earnings at $3.97 EPS, Q3 2026 earnings at $3.86 EPS, Q4 2026 earnings at $4.01 EPS, FY2026 earnings at $15.87 EPS, FY2027 earnings at $17.61 EPS, FY2028 earnings at $20.06 EPS and FY2029 earnings at $20.97 EPS.

BIIB has been the subject of a number of other research reports. Wall Street Zen upgraded Biogen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 28th. Piper Sandler increased their target price on Biogen from $115.00 to $118.00 and gave the company a "neutral" rating in a report on Friday, September 12th. Needham & Company LLC restated a "hold" rating on shares of Biogen in a report on Wednesday, September 24th. William Blair restated an "outperform" rating on shares of Biogen in a report on Wednesday, September 24th. Finally, HC Wainwright upped their price target on shares of Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Eleven research analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $180.69.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $143.66 on Thursday. Biogen has a one year low of $110.04 and a one year high of $192.16. The stock has a fifty day moving average of $141.00 and a 200-day moving average of $131.32. The company has a market capitalization of $21.06 billion, a PE ratio of 13.73, a price-to-earnings-growth ratio of 1.15 and a beta of 0.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The company had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same quarter in the prior year, the firm earned $5.28 EPS. The company's quarterly revenue was up 7.3% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 517 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the transaction, the insider directly owned 5,772 shares of the company's stock, valued at $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.18% of the stock is owned by insiders.

Hedge Funds Weigh In On Biogen

Hedge funds have recently bought and sold shares of the business. Generali Investments CEE investicni spolecnost a.s. increased its position in Biogen by 43.2% during the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 38,755 shares of the biotechnology company's stock worth $4,867,000 after buying an additional 11,695 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in Biogen by 6.5% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 416,960 shares of the biotechnology company's stock worth $57,057,000 after buying an additional 25,464 shares during the last quarter. Asset Management One Co. Ltd. increased its position in Biogen by 5.5% during the first quarter. Asset Management One Co. Ltd. now owns 61,420 shares of the biotechnology company's stock worth $8,405,000 after buying an additional 3,194 shares during the last quarter. Point72 Europe London LLP acquired a new position in Biogen during the first quarter worth $11,286,000. Finally, Motley Fool Asset Management LLC grew its position in shares of Biogen by 64.7% in the first quarter. Motley Fool Asset Management LLC now owns 6,809 shares of the biotechnology company's stock valued at $932,000 after purchasing an additional 2,676 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.